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Abstract 
Background: In Ethiopia, like in most other sub Saharan Africa countries, malaria remains a major public health 
problem with P.falciparum accounting for the highest number of deaths. Owing to its effectiveness and low cost, 
treatment with Sulfadoxine/Pyrimethamine (SP) was and is still the recommended first line treatment for 
uncomplicated P. falciparum malaria.  However, the rapid emergence of resistance is considered to be the main 
drawback for the use of this drug in malaria endemic areas. 
Objectives: This study is aimed at assessing the extent of resistance to SP by P. falciparum malaria. 
Methods: A cross sectional study, was conducted in Oct. 2003 in Jimma town.  The study included children under 15 
years of age who were infected with P.falciparum malaria and who have fulfilled the inclusion criteria. The patients 
were treated with the standard regimen of Sulfadoxine/Pyrimethamine. Clinical and parasitological responses to the 
drug sample were monitored for 14 days.   
Results: A total of 95 children below 15 years of age were considered for the study, out of whom 86 have completed 
the 14-day follow up with a 9.5% loss to follow up.  The age of the children ranged from one to 14 years 60 (63.2%) of 
them were males and 35 (36.8%) were females with a male to female ratio of 1.71. With regard to age distribution, 24 
(25.3%)were in the under-five-age category, 41(43.2%) in the age group 5-9, and 30 (31.6) were in the age group 10-
14.  Forty seven (54.7%) children responded successfully both clinically and parasitologically to SP treatment. 
Twenty-two (25.6%) children had late parasitological failure, and 17(19.7%) had late clinical failure. The mean 
parasite count at recruitment was 32,651 per µl with a range of 2,100 –190,000. The period time for clearance of 
parasitemia was 2.7 days (+ 2.53 SD). 
Conclusion: This study has shown that the prevalence of resistance to SP is on the increase, which may indicate the 
need for searching for affordable and effective substitutes to SP.  [Ethiop.J.Health Dev. 2005;19(1):11-15] 
 
Introduction 
Malaria remains as the major disease of public health 
importance in Ethiopia; and leads the list of top diseases 
for outpatient morbidity. It is among the leading causes 
of hospitalization and hospital deaths (1). 
 
It is also a significant health problem for many countries, 
and its effect has even worsened with the emergence of 
drug-resistant strains of the parasite. 
 
Sulphadoxine/Pyrimethamine remains to be the only drug 
of choice as first line treatment for uncomplicated 
P.falciparum malaria in most African countries 
(Chloroquine was replaced by Sulphadoxine/ 
Pyrimethamine as first line treatment for uncomplicated 
P.falciparum malaria in Ethiopia in 1999) (1). 
 
However, the rapid emergence of resistance and the 
slower clinical response are considered to be the main 
drawbacks in the use of this drug product in malaria-
endemic areas (2, 3). 
 
Inspite of the wide use of Sulphadoxine/Pyrimethamine 
over the last ten years in the country, an evaluation of the 
efficacy of these drugs from 1996 to 1998 found the drug 
to be highly effective in the treatment of uncomplicated 
P.falciparum malaria (1).  However, there is evidence 
that the prevalence of clinical resistance to Sulphadoxine/ 
Pyrimethamine in East Africa is on the increase (4). 
 
As the trend of malaria changes over time, the efficacy 
and effectiveness, tolerance and safety including mild 
side effects, as well as severe and life threatening adverse 
effects of the recommended treatment should be 
monitored.  Emphasis particularly should be given to 
monitoring the emergence of resistance to Sulphadoxine-
Pyrimethamine (1). 
 
Therefore, close monitoring of resistance patterns would 
be required to maximize the therapeutic benefits of this 
drug.  
 
No study has been conducted so far though personal 
observation from daily practice and informal 
communication with health professionals has raised 
doubts about the effectiveness of Sulphadoxine/ 
Pyrimethamine on P. falciparum malaria. 
 
Based on this notion, this study set the objective to 
determine the practical efficacy of single dose 
Sulfadoxine/Pyrimethamine intake in the routine 
treatment of uncomplicated P.falciparum malaria. 
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Methods 
The study was conducted in children who were screened 
at the Malaria Control Center in Jimma town, south west 
of Ethiopia in Oct.2003. 
 
The Sample size was determined to be 97, based on a 
50% expected proportion of treatment failure, 95% 
confidence interval and a 10% precision target (5).   
 
After informed consent was obtained from parents or 
guardians, children between the age of 6 months and 14 
years of age were included in the study by making user 
that they have fulfilled the following inclusion criteria: 
mono infection with Plasmodium falciparum, a 
parasitemia level of 2,000- 200,000/µl, absence of danger 
signs or signs of severe and complicated malaria 
according to the definition given by WHO (6), presence 
of auxillary temperature (> 37.5 oC), absence of other 
conditions like pneumonia which can cause fever, no use 
of SP two weeks prior to the study and if following visits 
were possible. 
 
Blood films were taken five times for each patient during 
the study (day 0, 2, 3, 7, and 14). Thick blood films were 
dried and stained with Giemsa stain at of a PH of 7.4 and 
were examined to determine parasite density (100 high 
power field (HPF) were used and the number of asexual 
parasites per HPF was recorded), according to the 
method described in the WHO Protocol (5).  Blood slide 
is considered negative if 100 fields on a thick film are 
examined and no parasites are seen. Parasite count was 
based on the number of asexual parasites observed 
against 200 leukocytes. This number was then multiplied 
by 40 to gain an approximate count per microlitre 
(parasitemia per µl = number of parasite x 8000/number 
of leukocytes).  
 
A case record form was completed and patients were 
given a single dose of Sulfadoxine/Pyrimethamine 
(Fansidar, Hoffman la Roche) based on body weight at a 
dose of 1.25mg per Kg Pyrimethamine or 25mg 
Sulfadoxine per Kg according to the WHO guideline (6). 
The dose was given under supervision and was repeated 
if vomiting occurred within one hour. Children with an 
auxillary temperature of 38.5 oC or higher were treated 
with Paracetamol (15mg per kg per dose taken orally 
every 6 hr for 24 hrs).  Parents or guardians were asked 
to bring their children on days 1,2,3,7 and 14 for follow-
up and or any other day if the illness worsened so that the 
child could be examined, temperature recorded and blood 
films are taken.  
 
Oral quinine was given to children with treatment 
failures while those with danger signs were referred to 
hospitals.  
 
The response to treatment was classified based on the 
WHO Protocol (6).  Early treatment failure (ETF) is 
defined as   parasitemia   higher   than   day   0  count  on  
day 2 irrespective of auxillary temperature >37.5oC or 
parasitemia on day 3 > 25% of count on Day 0. The 
definition of late clinical failure (LCF) is presence of 
parasitemia on any day from day 4 to 14 at a measured 
auxillary temperature of > 37.5oC, without previously 
meeting any of the criteria of ETF while late 
parasitological failure (LPF) was defined as the presence 
of parasitemia on day 14 and a measured auxillary 
temperature of less than 37.5oC, without previously 
meeting any of the criteria of ETF and LCF. Adequate 
clinical and parasitological response (ACPR) is defined 
as the absence of parasitemia on day 14 irrespective of 
auxillary temperature without previously meeting the 
criteria for early treatment or late clinical failure or late 
parasitological failure. 
 
The data were checked for completeness and the double 
entry system was employed while entering the data.   
Chi- Square and lifetime table analysis methods were 
used.  SPSS 11.0 for windows was applied for the 
analysis.  
 
Twenty percent of the blood slide samples were 
counterchecked for validity of parasitic count by a senior 
laboratory technologist.   
  
Result 
A total of 95 children below 15 years of age were 
considered for the study, out of whom 86 have completed 
the 14-day follow up with a 9.5% loss to follow up but 
their data was used during analysis using the life table 
method.  The entry characteristics are shown in Table 1. 
 
The age of the children ranged from 1 to 14 years. There 
were 60 (63.2%) males and 35 (36.8%) females with a 
male to female ratio of 1.71. With regard to age 
distribution, 24 (25.3%) were in the age group of less 
than five years, 41(43.2%) were in the age group of 5-9, 
and 30 (31.6%) were in the age group of 10-14. All 
patients come from Jimma Zone, 56.8% lived in Jimma 
town while the remaining resided in surrounding rural 
kebeles (Table 1). 
 
Table 1:  Baseline characteristics of children with 
uncomplicated P. falciparum malaria, Jimma town, 
South west Ethiopia, Oct. 2003 
Characteristics  
Number of patients 95 
Age (in years) 7.3 (1.14) 
Male (%) 63 
Parasitmia (per µl) 32651 (2100-190000) 
 
Using the WHO clinical treatment response criteria, 47 
(54.7%) children were found to have a successful 
response both clinically and parasitologically to SP 
treatment during the 14 day follow up period. Twenty-
two (25.6%) children had late parasitological failure, 
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17(19.7%) had late clinical failure and none of the 
children had early treatment failure.  (Table 2)   
 
The mean parasite count at recruitment was 32,651/µl 
with a range of 2100 to 190,000 and the mean time for 
clearance of parasitemia was 2.7 days (+ 2.53 SD). 
(Fig.1) 
 
The rate of clearance was the same in all the age groups 
and followed the same pattern of decrease in mean 
parasitic count in the first few days after treatment and an 
increase in the 7th and 14th days in those who failed to 
respond (Fig. 1). 
Table 2:  Patterns of P. falciparum resistance to 
SP, Jimma town, South west Ethiopia, Oct. 2003 
 N=86 % 
Resistance 39 45.3 
     ETF 0 0.0 
     LCF 17 19.7 
     LPF 22 25.6 
     ACPR 47 54.7 
ETF = Early Treatment Failure 
LCF = Late Clinical Failure 
LPF = Late Parasitological Failure 








































Figure 1:  Mean parasite count in relation to pattern of resistance, Jimma town, South west Ethiopia, Oct. 2003 
 
Discussion 
The mean parasite count at recruitment was 32,651 per µl 
with a range of 2,100 –190,000, which is lower than a 
finding reported in a study in the Kenya, which showed 
the mean parasite count to be 44,741 and with the range 
720 to 240,000 per µl. But, the mean time required for 
the clearance of parasitemia is somehow close to the 
Kenyan study, which had reported 2.5 days.(4)   
 
Sulfadoxine and Pyrimethamine are long but slow acting 
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216 hrs and 80–95 hrs respectively which explains the 
long time required for the clearance of parasitemia (7).  
 
The rate of parasitic clearance was the same in all the age 
groups and followed the same pattern of increase in 
parasitimia in the 7th and 14th days in those who failed to 
respond. Age, sex and parasitic load didn’t show 
statistically significant association with the response to 
treatment (p>0.05) unlike the case of a study in Somalia 
that reported that the degree of initial parasitimia seemed 
to influence the clinical outcome and degree of 
parasitimia at day 0(8). 
 
This study documents that a good number of 
parasitological failures, (about 20% and 40% of patients) 
had demonstrable parasite levels in their peripheral blood 
at 7th and 14th day respectively, showing that clinical 
criteria alone may underestimate the rate of treatment 
failure. 
 
Thirty-nine (45.3%) children had late treatment failure in 
our study unlike a similar prospective observational study 
conducted in Kenya in 1999 that found out a lower 
treatment failure (6.7% early treatment failure (ETF) and 
only 1.3% late treatment failure (LTF) (4). 
 
This finding may prove the assertion that the prevalence 
of clinical resistance to sulfadoxine /pyrimethamine in 
East Africa is on the increase (4). 
 
According to a study in Uganda, treatment failure based 
on clinical criteria occurred in 13 of 131 (10%) patients 
on Sulfadoxine /Pyrimethamine treatment, nine of 131 
(7%) on amodiaquine, and four of the 138 (3%) on the 
amodiaquine /sulfadoxine/ pyrimethamine.  Based on 
parasitological criteria, treatment failed in 26%, 16% and 
10% of these patients respectively (9). 
 
On the contrary, based on the WHO modified 14-day in 
vivo drug efficacy test for uncomplicated P. falciparum 
malaria, 4 (6%) of 67 Sulfadoxine /Pyrimethamine 
treated patients had therapeutic failures (2 ETFs and 2 
LTFs) in areas of the Pacific Coast region of Colombia.  
The relatively low level of therapeutic failures to 
Sulfadoxine /Pyrimethamine compared with other South 
American countries raised further questions regarding 
factors that might have prevented the rapid development 
of in vivo resistance to this drug combination (10).  
 
According to a study done in Somalia on the treatment of 
uncomplicated P. falciparum infection with Sulfadoxine 
Pyrimethamine, 98% (n=50) of the patients were reported 
to have achieved an adequate clinical response despite a 
parasitological failure rate of 76% RII/ RIII.  They 
concluded that doubts about the therapeutic life of 
Sulfadoxine /Pyrimethamine in relation to malaria are 
raised by high levels of resistance in the study area and 
underline the need to identify suitable alternatives (8). 
A study done on 405 Gambian children with 
uncomplicated P.falciparum found out a combination of 
Fansidar (Sulfadoxine /Pyrimethamine) plus Chloro-
quine was a more effective symptomatic treatment than 
Fansidar given alone, but neither the parasite cure rate 
nor the mean packed cell volume (PCV) was enhanced 
by use of the combination (11).  
 
A similar study done in central Ethiopia has suggested 
that the combination of Sulfadoxine/Pyrimethamine and 
Chloroquine is safer, effective and superior in fever 
clearance rate and useful to delay parasite resistance to 
SP (12).    
 
Another study stated the higher prevalence of SP 
treatment failure associated gametocytemia may 
contribute to increased transmission of antifolate resistant 
strains and further cautions against the use of 
Sulfadoxine/Pyrimethamine as monotherapy (13).  
 
As to the Somali study, the high degree of parasite 
resistance (76% RII/RIII) was explained by the absence 
of a functioning treatment policy and regulatory systems; 
Sulfadoxine/Pyrimethamine was made easily accessible 
in Somalia even for rural communities. Drug pressure 
associated with the wide spread use of sulfa- based 
antibiotics, e.g. Cotrimoxazole for the treatment of 
bacterial infections; might have added to the problem.  
The study concluded that clinical failure following the 
use of Sulfadoxine/Pyrimethamine can be expected 
sooner or later and that there is a clear need for looking 
beyond SP and identifying other suitable alternatives (8). 
 
Finally, Sulfadoxine/Pyrimethamine may no longer be 
considered adequate for treating P.falciparum in the 
study area as high level of resistance is documented 
which underlines the need to identify suitable 
alternatives. 
 
Therefore, alternative drugs like Dihydroartemisinine, 
Halofantrine, Mefloquine and combination therapies such 
as chlorproguanil-dapsone, atovaquone-proguanil and 
Artemisia annua herbal tea may have to be tested to avert 
the looming crisis. 
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